# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and maintains $7 p...
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and maintains $7 p...
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of...
Jefferies analyst Eun Yang assumes Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and raises Price Target to $8.
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.
RMAT designation follows FDA's review of available safety and efficacy data from the first three patients dosed with the lo...